{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:49:26Z","timestamp":1790617766142,"version":"4.1.0"},"reference-count":16,"publisher":"Society of Nuclear Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,9,4]]},"published-print":{"date-parts":[[2025,11]]},"DOI":"10.2967\/jnumed.125.270704","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T19:35:26Z","timestamp":1758828926000},"page":"1684-1687","source":"Crossref","is-referenced-by-count":4,"title":["First-Line [\n                    <sup>177<\/sup>\n                    Lu]Lu-PSMA-617 Therapy Without ADT, Chemotherapy, or Local Therapy for Metastatic Hormone-Sensitive Prostate Cancer"],"prefix":"10.2967","volume":"66","author":[{"given":"Vinay K.","family":"Giri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald M.","family":"Kolodny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc B.","family":"Garnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"2025110708450898000_66.11.1684.1","unstructured":"FDA expands Pluvicto\u2019s metastatic castration-resistant prostate cancer indication. Food and Drug Administration website. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-expands-pluvictos-metastatic-castration-resistant-prostate-cancer-indication. Accessed September 10, 2025."},{"key":"2025110708450898000_66.11.1684.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2025110708450898000_66.11.1684.3","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet."},{"key":"2025110708450898000_66.11.1684.4","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol."},{"key":"2025110708450898000_66.11.1684.5","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1470-2045(25)00009-9","article-title":"Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial","volume":"26","author":"Emmett","year":"2025","journal-title":"Lancet Oncol."},{"key":"2025110708450898000_66.11.1684.6","doi-asserted-by":"crossref","first-page":"e233460","DOI":"10.1148\/radiol.233460","article-title":"Quantitative 68Ga-PSMA-11 PET and clinical outcomes in metastatic castration-resistant prostate cancer following 177Lu-PSMA-617 (VISION Trial)","volume":"312","author":"Kuo","year":"2024","journal-title":"Radiology."},{"key":"2025110708450898000_66.11.1684.7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.223099"},{"key":"2025110708450898000_66.11.1684.8","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","article-title":"Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study","volume":"25","author":"Azad","year":"2024","journal-title":"Lancet Oncol."},{"key":"2025110708450898000_66.11.1684.9","first-page":"T7","article-title":"Peptide receptor radionuclide therapy (PRRT) with Lu-177 PSMA-617 vipivotide tetraxetan (Pluvicto) on a recently diagnosed prostatic cancer as initial first line therapy","volume":"64","author":"Arroyo","year":"2023","journal-title":"J Nucl Med."},{"key":"2025110708450898000_66.11.1684.10","doi-asserted-by":"crossref","first-page":"863101","DOI":"10.3389\/fnume.2022.863101","article-title":"An update to the pilot study of 177Lu-PSMA in low volume hormone-sensitive prostate cancer","volume":"2","author":"Priv\u00e9","year":"2022","journal-title":"Front Nucl Med."},{"key":"2025110708450898000_66.11.1684.11","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.1200\/JCO.2025.43.16_suppl.5009","article-title":"Lutetium-177-PSMA-617 in oligo-metastatic hormone sensitive prostate cancer (BULLSEYE trial)","volume":"43","author":"Priv\u00e9","year":"2025","journal-title":"J Clin Oncol."},{"key":"2025110708450898000_66.11.1684.12","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s43018-023-00539-6","article-title":"Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer","volume":"4","author":"Bakht","year":"2023","journal-title":"Nat Cancer."},{"key":"2025110708450898000_66.11.1684.13","doi-asserted-by":"crossref","first-page":"TPS5127","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS5127","article-title":"PSMA-delay castration (DC): an open-label, multicenter, randomized phase 3 study of [177Lu]Lu-PSMA-617 versus observation in patients with metachronous PSMA-positive oligometastatic prostate cancer (OMPC)","volume":"43","author":"Sartor","year":"2025","journal-title":"J Clin Oncol."},{"key":"2025110708450898000_66.11.1684.14","doi-asserted-by":"crossref","first-page":"TPS5116","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS5116","article-title":"PSMAddition: a phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SoC) and SoC alone in patients with metastatic hormone-sensitive prostate cancer","volume":"41","author":"Tagawa","year":"2023","journal-title":"J Clin Oncol."},{"key":"2025110708450898000_66.11.1684.15","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06165-9"},{"key":"2025110708450898000_66.11.1684.16","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1200\/JCO.2025.43.16_suppl.5020","article-title":"Clonal hematopoiesis (CH) in participants with metastatic castration-resistant prostate cancer (mCRPC) receiving 177Lu-PSMA-617 or cabazitaxel: an exploratory post-hoc analysis of a randomized phase II trial (TheraP; ANZUP 1603)","volume":"43","author":"Munzur","year":"2025","journal-title":"J Clin Oncol."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.270704","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T16:45:18Z","timestamp":1762533918000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.270704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":16,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,3]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.2967\/jnumed.125.270704"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.270704","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]}}}